

# Murray B Urowitz

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1200276/murray-b-urowitz-publications-by-year.pdf>  
**Version:** 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

188 papers	18,891 citations	52 h-index	136 g-index
214 ext. papers	22,385 ext. citations	4.6 avg, IF	6.16 L-index

#	Paper	IF	Citations
188	Comparison of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Systemic Lupus Erythematosus Classification Criteria With Two Sets of Earlier Systemic Lupus Erythematosus Classification Criteria. <i>Arthritis Care and Research</i> , <b>2021</b> , 73, 1231-1235	4.7	10
187	Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 1-2	2.4	4
186	Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and Medications. <i>Arthritis Care and Research</i> , <b>2021</b> , 73, 1789-1795	4.7	2
185	Medium versus high initial prednisone dose for remission induction in lupus nephritis: A propensity score matched analysis. <i>Arthritis Care and Research</i> , <b>2021</b> , 73, 1789-1795	4.7	3
184	Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset. <i>Lupus</i> , <b>2021</b> , 30, 1283-1288	2.6	2
183	Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus. <i>Rheumatology</i> , <b>2021</b> , 60, 5397-5407	3.9	10
182	Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception Cohort. <i>Arthritis and Rheumatology</i> , <b>2021</b> , 73, 2293-2302	9.5	2
181	Assessment of cardiovascular risk tools as predictors of cardiovascular disease events in systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , <b>2021</b> , 8, 1-2	4.6	3
180	Barriers to medication adherence and degree of nonadherence in a systemic lupus erythematosus (SLE) outpatient population. <i>Rheumatology International</i> , <b>2021</b> , 41, 1457-1464	3.6	2
179	Gradual Glucocorticosteroid Withdrawal Is Safe in Clinically Quiescent Systemic Lupus Erythematosus. <i>ACR Open Rheumatology</i> , <b>2021</b> , 3, 550-557	3.5	2
178	Effect of Disease Activity on Organ Damage Progression in Systemic Lupus Erythematosus: University of Toronto Lupus Clinic Cohort. <i>Journal of Rheumatology</i> , <b>2021</b> , 48, 67-73	4.1	8
177	Systemic glucocorticoids <b>2021</b> , 597-609		
176	Propensity Score Methods in Rare Disease: A Demonstration Using Observational Data in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , <b>2021</b> , 48, 321-325	4.1	4
175	Hydroxychloroquine shortages among patients with systemic lupus erythematosus during the COVID-19 pandemic: experience of the Systemic Lupus International Collaborating Clinics. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 1-2	2.4	21
174	Response to placebo in non-renal, non-neuropsychiatric systemic lupus erythematosus: a systematic review and pooled analysis. <i>Rheumatology</i> , <b>2021</b> , 60, 73-80	3.9	1
173	Acquired low immunoglobulin levels and risk of clinically relevant infection in adult patients with systemic lupus erythematosus: a cohort study. <i>Rheumatology</i> , <b>2021</b> , 60, 1456-1464	3.9	4
172	Factors Associated With Rapid Progression to Endstage Kidney Disease in Lupus Nephritis. <i>Journal of Rheumatology</i> , <b>2021</b> , 48, 228-231	4.1	1

171	New EULAR/ACR 2019 SLE Classification Criteria: defining ominousity in SLE. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,	2.4	6
170	The baseline interferon signature predicts disease severity over the subsequent 5 years in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , <b>2021</b> , 23, 29	5.7	9
169	Metrics in Disease Activity Measures in Systemic Lupus Erythematosus <b>2021</b> , 111-146		
168	European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,	2.4	10
167	Lower vitamin D is associated with metabolic syndrome and insulin resistance in systemic lupus: data from an international inception cohort. <i>Rheumatology</i> , <b>2021</b> , 60, 4737-4747	3.9	5
166	Immunoglobulin levels in systemic lupus erythematosus: A narrative review. <i>Lupus</i> , <b>2021</b> , 30, 867-875	2.6	3
165	Identifying a Response for the Systemic Lupus Erythematosus Disease Activity 2000 Glucocorticoid Index. <i>Arthritis Care and Research</i> , <b>2021</b> , 73, 1243-1249	4.7	5
164	Response to: Correspondence on "New EULAR/ACR 2019 SLE classification criteria: defining ominousity in SLE" by Whittall Garcia. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,	2.4	
163	Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies.. <i>Lupus Science and Medicine</i> , <b>2021</b> , 8,	4.6	5
162	Prediction of hospitalizations in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI). <i>Arthritis Care and Research</i> , <b>2020</b> ,	4.7	2
161	Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort. <i>Arthritis and Rheumatology</i> , <b>2020</b> , 72, 1734-1740	9.5	7
160	Impact of the new American College of Cardiology/American Heart Association definition of hypertension on atherosclerotic vascular events in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 612-617	2.4	17
159	Atherosclerotic Vascular Events in Systemic Lupus Erythematosus: An Evolving Story. <i>Journal of Rheumatology</i> , <b>2020</b> , 47, 66-71	4.1	11
158	Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach. <i>Arthritis Care and Research</i> , <b>2020</b> , 72, 1800-1808	4.7	7
157	Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index. <i>Arthritis and Rheumatology</i> , <b>2020</b> , 72, 658-666	9.5	11
156	Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , <b>2020</b> , 106, 102340	15.5	15
155	Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 356-362	2.4	18
154	Comparative analysis of long-term organ damage in patients with systemic lupus erythematosus using belimumab versus standard therapy: a post hoc longitudinal study. <i>Lupus Science and Medicine</i> , <b>2020</b> , 7,	4.6	5

153	Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 1333-1339	2.4	16
152	Association of systemic lupus erythematosus (SLE) genetic susceptibility loci with lupus nephritis in childhood-onset and adult-onset SLE. <i>Rheumatology</i> , <b>2020</b> , 59, 90-98	3.9	21
151	Construction of a Frailty Index as a Novel Health Measure in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , <b>2020</b> , 47, 72-81	4.1	21
150	Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , <b>2020</b> , 72, 67-77	9.5	18
149	Advanced Chronic Kidney Disease in Lupus Nephritis: Is Dialysis Inevitable?. <i>Journal of Rheumatology</i> , <b>2020</b> , 47, 1366-1373	4.1	3
148	Multicriteria decision analysis process to develop new classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 634-640	2.4	35
147	Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort. <i>Journal of Rheumatology</i> , <b>2019</b> , 46, 492-500	4.1	7
146	All-cause, cause-specific and age-specific standardised mortality ratios of patients with systemic lupus erythematosus in Ontario, Canada over 43 years (1971-2013). <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 802-806	2.4	52
145	Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , <b>2019</b> , 71, 1297-1307	9.5	15
144	Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. <i>Rheumatology</i> , <b>2019</b> , 58, 1259-1267	3.9	5
143	Abnormal Cardiac Biomarkers in Patients with Systemic Lupus Erythematosus and No Prior Heart Disease: A Consequence of Antimalarials?. <i>Journal of Rheumatology</i> , <b>2019</b> , 46, 64-69	4.1	10
142	Antinuclear Antibody-Negative Systemic Lupus Erythematosus in an International Inception Cohort. <i>Arthritis Care and Research</i> , <b>2019</b> , 71, 893-902	4.7	46
141	Clinical Remission and Low Disease Activity Outcomes Over 10 Years in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , <b>2019</b> , 71, 822-828	4.7	25
140	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 1151-1159	2.4	344
139	2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , <b>2019</b> , 71, 1400-1412	9.5	488
138	Dr. Tselios, reply. <i>Journal of Rheumatology</i> , <b>2019</b> , 46, 1422	4.1	
137	FRI0195 EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL (DZP) IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): A RANDOMISED, PLACEBO (PBO)-CONTROLLED STUDY <b>2019</b> ,		5
136	Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 1010-1012	2.4	4

135 Differential Diagnosis and Disease Associations **2019**, 598-605

134 Organ damage in patients treated with belimumab versus standard of care: a propensity score-matched comparative analysis. *Annals of the Rheumatic Diseases*, **2019**, 78, 372-379 2.4 32

133 Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. *Arthritis and Rheumatology*, **2019**, 71, 281-289 9.5 31

132 Antimalarial-induced Cardiomyopathy in Systemic Lupus Erythematosus: As Rare as Considered?. *Journal of Rheumatology*, **2019**, 46, 391-396 4.1 20

131 How can we define low disease activity in systemic lupus erythematosus?. *Seminars in Arthritis and Rheumatism*, **2019**, 48, 1035-1040 5.3 15

130 A novel lupus activity index accounting for glucocorticoids: SLEDAI-2K glucocorticoid index. *Rheumatology*, **2018**, 57, 1370-1376 3.9 16

129 Smoking Is the Most Significant Modifiable Lung Cancer Risk Factor in Systemic Lupus Erythematosus. *Journal of Rheumatology*, **2018**, 45, 393-396 4.1 23

128 Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort. *Rheumatology*, **2018**, 57, 677-687 3.9 20

127 Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. *Arthritis Care and Research*, **2018**, 70, 1478-1487 4.7 36

126 Clinical trial parameters that influence outcomes in lupus trials that use the systemic lupus erythematosus responder index. *Rheumatology*, **2018**, 57, 125-133 3.9 8

125 Rituximab for Sight-Threatening Lupus-Related Retinal Vasculitis. *Journal of Clinical Rheumatology*, **2018**, 24, 93-94 1.1 2

124 Practice Variations in the Diagnosis, Monitoring, and Treatment of Systemic Lupus Erythematosus in Canada. *Journal of Rheumatology*, **2018**, 45, 1440-1447 4.1 10

123 Monophasic Disease Course in Systemic Lupus Erythematosus. *Journal of Rheumatology*, **2018**, 45, 1131-1135 4.1 6

122 Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach. *Arthritis Care and Research*, **2018**, 70, 1294-1302 4.7 13

121 More Consistent Antimalarial Intake in First 5 Years of Disease Is Associated with Better Prognosis in Patients with Systemic Lupus Erythematosus. *Journal of Rheumatology*, **2018**, 45, 90-94 4.1 12

120 Canadian Rheumatology Association Recommendations for the Assessment and Monitoring of Systemic Lupus Erythematosus. *Journal of Rheumatology*, **2018**, 45, 1426-1439 4.1 33

119 Disease Outcomes in Glucocorticosteroid-Naive Patients With Systemic Lupus Erythematosus. *Arthritis Care and Research*, **2017**, 69, 252-256 4.7 7

118 A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). *Annals of the Rheumatic Diseases*, **2017**, 76, 554-561 2.4 175

117	Psoriasis in systemic lupus erythematosus: a single-center experience. <i>Clinical Rheumatology</i> , <b>2017</b> , 36, 879-884	3.9	16
116	Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 543-546	2.4	80
115	Prevalence and associated factors of resting electrocardiogram abnormalities among systemic lupus erythematosus patients without cardiovascular disease. <i>Arthritis Research and Therapy</i> , <b>2017</b> , 19, 31	5.7	9
114	Hospitalizations in Patients with Systemic Lupus Erythematosus in an Academic Health Science Center. <i>Journal of Rheumatology</i> , <b>2017</b> , 44, 1173-1178	4.1	21
113	Comparison of systemic lupus erythematosus (SLE) patients managed early after diagnosis in specialty versus community care clinics. <i>Clinical Rheumatology</i> , <b>2017</b> , 36, 1773-1778	3.9	5
112	Evolution of Risk Factors for Atherosclerotic Cardiovascular Events in Systemic Lupus Erythematosus: A Longterm Prospective Study. <i>Journal of Rheumatology</i> , <b>2017</b> , 44, 1841-1849	4.1	32
111	Cardiovascular and Pulmonary Manifestations of Systemic Lupus Erythematosus. <i>Current Rheumatology Reviews</i> , <b>2017</b> , 13, 206-218	1.6	43
110	Reply. <i>Arthritis Care and Research</i> , <b>2017</b> , 69, 1934	4.7	
109	Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 1837-1844	2.4	60
108	The utility of lupus serology in predicting outcomes of renal transplantation in lupus patients: Systematic literature review and analysis of the Toronto lupus cohort. <i>Seminars in Arthritis and Rheumatism</i> , <b>2017</b> , 46, 791-797	5.3	3
107	Defining Low Disease Activity in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , <b>2017</b> , 69, 997-1003	4.7	45
106	Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study. <i>Arthritis Research and Therapy</i> , <b>2017</b> , 19, 287	5.7	1
105	Systemic lupus erythematosus and pulmonary arterial hypertension: links, risks, and management strategies. <i>Open Access Rheumatology: Research and Reviews</i> , <b>2017</b> , 9, 1-9	2.4	19
104	The frequency and outcome of lupus nephritis: results from an international inception cohort study. <i>Rheumatology</i> , <b>2016</b> , 55, 252-62	3.9	210
103	Systemic lupus erythematosus. <i>Nature Reviews Disease Primers</i> , <b>2016</b> , 2, 16039	51.1	422
102	Dr. Tselios, et al reply. <i>Journal of Rheumatology</i> , <b>2016</b> , 43, 1767	4.1	
101	Does Renin-Angiotensin System Blockade Protect Lupus Nephritis Patients From Atherosclerotic Cardiovascular Events? A Case-Control Study. <i>Arthritis Care and Research</i> , <b>2016</b> , 68, 1497-504	4.7	9
100	Mycophenolate Mofetil in Nonrenal Manifestations of Systemic Lupus Erythematosus: An Observational Cohort Study. <i>Journal of Rheumatology</i> , <b>2016</b> , 43, 552-8	4.1	26



99	Optimal Monitoring For Coronary Heart Disease Risk in Patients with Systemic Lupus Erythematosus: A Systematic Review. <i>Journal of Rheumatology</i> , <b>2016</b> , 43, 54-65	4.1	47
98	Modified Framingham Risk Factor Score for Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , <b>2016</b> , 43, 875-9	4.1	46
97	Dyslipidemia in systemic lupus erythematosus: just another comorbidity?. <i>Seminars in Arthritis and Rheumatism</i> , <b>2016</b> , 45, 604-10	5.3	56
96	Systemic Glucocorticoids <b>2016</b> , 521-531		3
95	A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach. <i>Arthritis and Rheumatology</i> , <b>2016</b> , 68, 1932-44	9.5	27
94	Hydroxychloroquine-Induced Cardiomyopathy in Systemic Lupus Erythematosus. <i>Journal of Clinical Rheumatology</i> , <b>2016</b> , 22, 287-8	1.1	16
93	Interferon- $\gamma$ Induces altered transitional B cell signaling and function in Systemic Lupus Erythematosus. <i>Journal of Autoimmunity</i> , <b>2015</b> , 58, 100-10	15.5	29
92	Costs associated with severe and nonsevere systemic lupus erythematosus in Canada. <i>Arthritis Care and Research</i> , <b>2015</b> , 67, 431-6	4.7	17
91	Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , <b>2015</b> , 67, 1837-47	9.5	77
90	Anti-dsDNA and Antichromatin Antibody Isotypes in Serologically Active Clinically Quiescent Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 810-6	4.1	21
89	Safety and efficacy of hCDR1 (Edratide) in patients with active systemic lupus erythematosus: results of phase II study. <i>Lupus Science and Medicine</i> , <b>2015</b> , 2, e000104	4.6	39
88	SLEDAI-2K Does Not Conceal Worsening in a Particular System When There Is Overall Improvement. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 1401-5	4.1	5
87	Lack of Interferon and Proinflammatory Cyto/chemokines in Serologically Active Clinically Quiescent Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 2318-26	4.1	14
86	Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 1530-6	2.4	51
85	Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 1706-13	2.4	250
84	Utility of untimed single urine protein/creatinine ratio as a substitute for 24-h proteinuria for assessment of proteinuria in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , <b>2015</b> , 17, 296	5.7	13
83	Anti-nucleosome antibodies outperform traditional biomarkers as longitudinal indicators of disease activity in systemic lupus erythematosus. <i>Rheumatology</i> , <b>2015</b> , 54, 449-57	3.9	28
82	Isolated hematuria and sterile pyuria may indicate systemic lupus erythematosus activity. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 437-40	4.1	11

81	Lymphoma risk in systemic lupus: effects of disease activity versus treatment. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 138-42	2.4	83
80	Switching treatment between mycophenolate mofetil and azathioprine in lupus patients: indications and outcomes. <i>Arthritis Care and Research</i> , <b>2014</b> , 66, 1905-9	4.7	12
79	Do current arterial hypertension treatment guidelines apply to systemic lupus erythematosus patients? a critical appraisal. <i>Seminars in Arthritis and Rheumatism</i> , <b>2014</b> , 43, 521-5	5.3	28
78	Time to recovery from proteinuria in patients with lupus nephritis receiving standard treatment. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 688-97	4.1	57
77	American College of Rheumatology criteria at inception, and accrual over 5 years in the SLICC inception cohort. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 875-80	4.1	17
76	Prolonged clinical remission in patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 1808-16	4.1	68
75	Cancer risk in systemic lupus: an updated international multi-centre cohort study. <i>Journal of Autoimmunity</i> , <b>2013</b> , 42, 130-5	15.5	194
74	Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study. <i>Arthritis and Rheumatism</i> , <b>2013</b> , 65, 2887-97		65
73	Systemic lupus erythematosus: an update on current pharmacotherapy and future directions. <i>Expert Opinion on Biological Therapy</i> , <b>2013</b> , 13, 723-37	5.4	19
72	Outcome measures in systemic lupus erythematosus. <i>Indian Journal of Rheumatology</i> , <b>2013</b> , 8, S46-S53	0.5	7
71	Comparison of three anti-dsDNA assays: performance and correlation with systemic lupus erythematosus disease activity. <i>Clinical Biochemistry</i> , <b>2013</b> , 46, 317-20	3.5	21
70	The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , <b>2013</b> , 40, 831-41	4.1	79
69	Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, 1308-14	2.4	65
68	In memoriam - Hugh A. Smythe, 1927-2012. <i>Journal of Rheumatology</i> , <b>2013</b> , 40, 343-7	4.1	1
67	Recommendations for frequency of visits to monitor systemic lupus erythematosus in asymptomatic patients: data from an observational cohort study. <i>Journal of Rheumatology</i> , <b>2013</b> , 40, 630-3	4.1	14
66	Clinical Measures, Metrics, and Indices <b>2013</b> , 563-581		3
65	High-sensitivity C-reactive protein as a marker of cardiovascular risk in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>2012</b> , 64, 3052-3		13
64	Outcomes in patients with systemic lupus erythematosus with and without a prolonged serologically active clinically quiescent period. <i>Arthritis Care and Research</i> , <b>2012</b> , 64, 511-8	4.7	60



63	Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>2012</b> , 64, 2677-86		2688
62	Ability of non-fasting and fasting triglycerides to predict coronary artery disease in lupus patients. <i>Rheumatology</i> , <b>2012</b> , 51, 528-34	3.9	20
61	Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 1502-9	2.4	115
60	Persistent proteinuria and dyslipidemia increase the risk of progressive chronic kidney disease in lupus erythematosus. <i>Kidney International</i> , <b>2011</b> , 79, 914-20	9.9	47
59	Importance of cumulative exposure to elevated cholesterol and blood pressure in development of atherosclerotic coronary artery disease in systemic lupus erythematosus: a prospective proof-of-concept cohort study. <i>Arthritis Research and Therapy</i> , <b>2011</b> , 13, R156	5.7	61
58	Peripheral neuropathy in patients with systemic lupus erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , <b>2011</b> , 41, 203-11	5.3	94
57	Autoantibody response to adjuvant and nonadjuvant H1N1 vaccination in systemic lupus erythematosus. <i>Arthritis Care and Research</i> , <b>2011</b> , 63, 1517-20	4.7	20
56	Mycophenolate mofetil for induction treatment of lupus nephritis: a systematic review and metaanalysis. <i>Journal of Rheumatology</i> , <b>2011</b> , 38, 69-78	4.1	84
55	Optimal frequency of visits for patients with systemic lupus erythematosus to measure disease activity over time. <i>Journal of Rheumatology</i> , <b>2011</b> , 38, 60-3	4.1	12
54	Development and initial validation of the systemic lupus erythematosus disease activity index 2000 responder index 50. <i>Journal of Rheumatology</i> , <b>2011</b> , 38, 275-84	4.1	54
53	Prolonged serologically active clinically quiescent systemic lupus erythematosus: frequency and outcome. <i>Journal of Rheumatology</i> , <b>2010</b> , 37, 1822-7	4.1	90
52	Variability over time and correlates of cholesterol and blood pressure in systemic lupus erythematosus: a longitudinal cohort study. <i>Arthritis Research and Therapy</i> , <b>2010</b> , 12, R125	5.7	20
51	The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>2010</b> , 62, 863-8		203
50	The 1000 Canadian faces of lupus: determinants of disease outcome in a large multiethnic cohort. <i>Journal of Rheumatology</i> , <b>2009</b> , 36, 1200-8	4.1	92
49	Myocardial perfusion imaging in assessing risk of coronary events in patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , <b>2009</b> , 36, 288-94	4.1	26
48	Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>2009</b> , 61, 1152-8		90
47	Epidemiology of atherosclerosis in systemic lupus erythematosus. <i>Current Rheumatology Reports</i> , <b>2009</b> , 11, 248-54	4.9	32
46	Risk factors for development of coronary artery disease in women with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , <b>2009</b> , 36, 2454-61	4.1	57

45	Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , <b>2008</b> , 35, 2152-8	4.1	229
44	The SLICC inception cohort for atherosclerosis. <i>Current Rheumatology Reports</i> , <b>2008</b> , 10, 281-5	4.9	9
43	Should all patients with systemic lupus erythematosus receive cardioprotection with statins?. <i>Nature Clinical Practice Rheumatology</i> , <b>2007</b> , 3, 536-7		6
42	Atherosclerotic vascular events in a single large lupus cohort: prevalence and risk factors. <i>Journal of Rheumatology</i> , <b>2007</b> , 34, 70-5	4.1	83
41	Summarizing disease features over time: II. Variability measures of SLEDAI-2K. <i>Journal of Rheumatology</i> , <b>2007</b> , 34, 336-40	4.1	23
40	Outcomes in patients with active lupus nephritis requiring immunosuppressives who never received cyclophosphamide. <i>Journal of Rheumatology</i> , <b>2007</b> , 34, 1491-6	4.1	12
39	Association between serum total cholesterol level and renal outcome in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>2006</b> , 54, 2211-9		21
38	Ethnic variation in disease patterns and health outcomes in systemic lupus erythematosus. <i>Journal of Rheumatology</i> , <b>2006</b> , 33, 1990-5	4.1	41
37	Anti-dsDNA antibody testing by Farr and ELISA techniques is not equivalent. <i>Journal of Rheumatology</i> , <b>2006</b> , 33, 1785-8	4.1	35
36	The effect of menopause on disease activity in systemic lupus erythematosus. <i>Journal of Rheumatology</i> , <b>2006</b> , 33, 2192-8	4.1	36
35	Contributions of observational cohort studies in systemic lupus erythematosus: the university of toronto lupus clinic experience. <i>Rheumatic Disease Clinics of North America</i> , <b>2005</b> , 31, 211-21, v	2.4	48
34	Premature atherosclerosis in systemic lupus erythematosus. <i>Rheumatic Disease Clinics of North America</i> , <b>2005</b> , 31, 329-54, vii-viii	2.4	75
33	Incidence rates of arterial and venous thrombosis after diagnosis of systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>2005</b> , 53, 609-12		61
32	Adjusted mean Systemic Lupus Erythematosus Disease Activity Index-2K is a predictor of outcome in SLE. <i>Journal of Rheumatology</i> , <b>2005</b> , 32, 824-7	4.1	97
31	Prolonged remission in systemic lupus erythematosus. <i>Journal of Rheumatology</i> , <b>2005</b> , 32, 1467-72	4.1	76
30	Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. <i>Arthritis and Rheumatism</i> , <b>2003</b> , 48, 3159-67		271
29	Single photon emission computed tomography dual isotope myocardial perfusion imaging in women with systemic lupus erythematosus. II. Predictive factors for perfusion abnormalities. <i>Journal of Rheumatology</i> , <b>2003</b> , 30, 288-91	4.1	25
28	Accrual of organ damage over time in patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , <b>2003</b> , 30, 1955-9	4.1	185

27	Summarizing disease features over time: I. Adjusted mean SLEDAI derivation and application to an index of disease activity in lupus. <i>Journal of Rheumatology</i> , <b>2003</b> , 30, 1977-82	4.1	108
26	Systemic lupus erythematosus disease activity index 2000. <i>Journal of Rheumatology</i> , <b>2002</b> , 29, 288-91	4.1	1602
25	Role of specialty care in the management of patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , <b>2002</b> , 29, 1207-10	4.1	12
24	Factors associated with refractory renal disease in patients with systemic lupus erythematosus: The role of patient nonadherence. <i>Arthritis and Rheumatism</i> , <b>2000</b> , 13, 406-408		44
23	Atherosclerosis and systemic lupus erythematosus. <i>Current Rheumatology Reports</i> , <b>2000</b> , 2, 19-23	4.9	27
22	Premature atherosclerosis in systemic lupus erythematosus. <i>Rheumatic Disease Clinics of North America</i> , <b>2000</b> , 26, 257-78	2.4	101
21	Factors associated with refractory renal disease in patients with systemic lupus erythematosus: The role of patient nonadherence <b>2000</b> , 13, 406		3
20	The SLICC/ACR damage index: progress report and experience in the field. <i>Lupus</i> , <b>1999</b> , 8, 632-7	2.6	64
19	The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>1997</b> , 40, 809-13		505
18	The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>1996</b> , 39, 363-9		1688
17	Malignancy in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>1996</b> , 39, 1050-4		179
16	Kidney biopsy in systemic lupus erythematosus. III. Survival analysis controlling for clinical and laboratory variables. <i>Arthritis and Rheumatism</i> , <b>1994</b> , 37, 559-67		56
15	Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. <i>Arthritis and Rheumatism</i> , <b>1992</b> , 35, 630-40		3596
14	Comparison of azathioprine, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial. <i>Arthritis and Rheumatism</i> , <b>1992</b> , 35, 849-56		91
13	Accelerated nodulosis during azathioprine therapy. <i>Arthritis and Rheumatism</i> , <b>1991</b> , 34, 123-4		23
12	Kidney biopsy in systemic lupus erythematosus. II. Survival analyses according to biopsy results. <i>Arthritis and Rheumatism</i> , <b>1991</b> , 34, 1268-73		61
11	Pregnancy outcome following first trimester exposure to chloroquine. <i>American Journal of Perinatology</i> , <b>1991</b> , 8, 174-8	3.3	92
10	Lupus retinopathy. Patterns, associations, and prognosis. <i>Arthritis and Rheumatism</i> , <b>1988</b> , 31, 1105-10		161

9	67Gallium lung scans in progressive systemic sclerosis. <i>Arthritis and Rheumatism</i> , <b>1983</b> , 26, 969-74		25
8	The significance of thrombocytopenia in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>1983</b> , 26, 1181-6		51
7	Systemic lupus erythematosus and diffuse soft tissue calcifications. <i>International Journal of Dermatology</i> , <b>1983</b> , 22, 416-8	1.7	9
6	Serologically active clinically quiescent systemic lupus erythematosus: a discordance between clinical and serologic features. <i>American Journal of Medicine</i> , <b>1979</b> , 66, 210-5	2.4	117
5	The bimodal mortality pattern of systemic lupus erythematosus. <i>American Journal of Medicine</i> , <b>1976</b> , 60, 221-5	2.4	735
4	Mixed leukocyte reaction in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , <b>1976</b> , 19, 532-8		10
3	The clinical significance of immune complexes in rheumatoid disease. <i>Annals of the New York Academy of Sciences</i> , <b>1975</b> , 256, 338-41	6.5	5
2	Asymptomatic spondylodiscitis. An unusual feature of ankylosing spondylitis. <i>Arthritis and Rheumatism</i> , <b>1974</b> , 17, 487-93		28
1	Studies into the occurrence of soluble antigen-antibody complexes in disease. V. Second assessment of correlation between the rheumatoid biologically active factor (RBAF) and the clinical features of rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , <b>1973</b> , 16, 225-30		11